| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447456 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
Oral SU-014813 50Â mg/day with docetaxel 75Â mg/m2 is a clinically feasible regimen with a manageable safety profile and anti-tumour activity. Further development is warranted in patients with melanoma and GIST.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M.J.A. de Jonge, H. Dumez, J.J.E.M. Kitzen, B. Beuselinck, J. Verweij, R. Courtney, A. Battista, N. Brega, P. Schöffski,